Drug
Nyx 2925
Nyx 2925: highest development phase Phase 2, developed by Aptinyx. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Aptinyx
Trials
| Drug | Phase | Indication |
|---|---|---|
| NYX-2925 50 mg NCT04146896 | Phase 2 | Diabetic Peripheral Neuropathic Pain |
| NYX-2925 NCT04147858 | Phase 2 | Fibromyalgia |
| NYX-2925 NCT03249103 | Phase 2 | Fibromyalgia |
| NYX-2925 NCT03219320 | Phase 2 | Diabetic Peripheral Neuropathy |
| NYX-2925 NCT02834741 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Nyx 2925 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.